Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2019): Katoh T+, Low Urin Tract Symptoms Sep, Epub ahead of print≤ 6% (with mirabegron)
- (2019): Katoh T+, Low Urin Tract Symptoms Sep, Epub ahead of print (with mirabegron)
QT interval prolonged / QT prolongation
- (2019): Katoh T+, Low Urin Tract Symptoms Sep, Epub ahead of print (with mirabegron)
- (2019): Katoh T+, Low Urin Tract Symptoms Sep, Epub ahead of print (with mirabegron)